UK to introduce clinical trial reforms
New clinical trial regulations are coming into effect this week (28 April) in the UK, with the changes being the largest package of reforms in over 20 years.
Delivered by the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA), the changes will include faster assessment of first in human trials and the introduction of notifiable trials, a fast-track route to allow lower-risk trials to start sooner and modification to be approved quicker.
The MHRA hopes that the reforms will make it easier to start lower-risk studies strengthen support for early-stage research and embrace new approaches, including use of early safety data from overseas studies and the use of computer model simulations to help predict how medicines might behave before they are used in patients.
The reforms follow steps made by the MHRA and HRA to deliver streamlined approvals for clinical trials. The government has set itself a target to reduce clinical trial set-up times to 150 days as part of its 10-year plan for the NHS. Latest figures show that set-up times have fallen to 122 days for studies going through and HRA reducing set-up times from 169 days to just 122 days for studies going through combined safety and ethical review.
As part of the new reforms, the Route B substantial modification pathway will be mandated, enabling eligible medication to be automatically approved unless concerns are raised within two weeks informing the sponsor that a full assessment in being undertaken.
Also included within the reforms are the legal requirements for registering clinical trials and publishing summary results. This is to ensure greater transparency and broadening access.
Dr Zubir Ahmed, Health Innovation and Safety Minister, said: “This is a landmark moment for patients, researchers, and our thriving life sciences sector that will make a real, tangible difference for thousands of people waiting for new treatments.
“By introducing faster routes for lower-risk trials, embracing modern technology, and making the system simpler to navigate, we are reinforcing the UK’s position as one of the most attractive places in the world to invest in cutting-edge research.”
MHRA Chief Executive, Lawrence Tallon, added: “These reforms to clinical trial regulations are a boost both for patients and industry investment in R&D in this country. They will help to make the UK a more attractive, internationally competitive destination for both commercial and non-commercial clinical research. Most importantly, patients will benefit from earlier access to the latest, innovative medicines.
“We have listened carefully to the needs of patients, clinicians, researchers and industry to ensure we are delivering the most efficient, streamlined approvals process without compromising safety.”
